iscalimab

targets CD40

Also Known As:

CFZ-533; CFZ533; NVP-CFZ533

Networked: 8 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iscalimab: 8
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iscalimab: 8
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iscalimab: 8

Experts

1.	Rush, James S: 3 articles (01/2020 - 11/2018)
2.	Rubic-Schneider, Tina: 2 articles (01/2022 - 11/2018)
3.	Ulrich, Peter: 2 articles (01/2022 - 11/2018)
4.	Colin, Laurence: 2 articles (01/2020 - 01/2020)
5.	Espie, Pascal: 2 articles (01/2020 - 11/2018)
6.	Gergely, Peter: 2 articles (01/2020 - 01/2020)
7.	Sickert, Denise: 2 articles (01/2020 - 11/2018)
8.	Espié, Pascal J: 1 article (01/2022)
9.	Flandre, Thierry D: 1 article (01/2022)
10.	Mansfield, Keith G: 1 article (01/2022)

Related Diseases

1.	Hyperthyroidism 01/01/2020 - "Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. " 01/01/2020 - "A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial." 01/01/2020 - "Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. "
2.	Sjogren's Syndrome (Sjogren Syndrome) 11/01/2020 - "Although early in development, the promising results in Sjogren's syndrome with iscalimab and ianalumab should make the Sjogren's syndrome community quite hopeful of future drug approvals. "
3.	Myasthenia Gravis 11/20/2023 - "Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study." 03/01/2019 - "Rozanolixizumab, CFZ533, belimumab, and bortezomib are B-cell-related therapies that are in the early stages of evaluation in treating myasthenia gravis. "
4.	Opportunistic Infections (Opportunistic Infection) 01/01/2022 - "Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study."
5.	Rheumatoid Arthritis 01/01/2020 - "We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rheumatoid arthritis patients. " 01/01/2020 - "Rheumatoid arthritis patients (n = 20) received single doses of intravenous iscalimab (10 or 30 mg/kg) or placebo. "

Related Drugs and Biologics

1.	ianalumab
2.	Monoclonal Antibodies
3.	iscalimab
4.	Blocking Antibodies
5.	Thyrotropin Receptors (Thyrotropin Receptor)
6.	Peptides (Polypeptides)
7.	Antibodies
8.	Bortezomib (Velcade)
9.	Rituximab (Mabthera)
10.	belimumab

Related Therapies and Procedures

1.	Therapeutics
2.	Transplantation